Summary The utility of current chemotherapeutic regimens in the treatment of AIDS-related Kaposi 44 (18.5%) had stable disease and two (0.8%) had disease progression. SL-DOX was well tolerated: ten patients discontinued therapy because of adverse events, in four cases because of neutropenia. Grade 3 or 4 neutropenia occurred after 281 of 2023 cycles (13.9%) but involved 137 of 240 patients (57.1%) for whom data were available. SL-DOX has substantial activity in AIDS-KS. Best response is typically seen after fewer than three cycles of chemotherapy and in some cases may be prolonged. The most important adverse event is neutropenia, which occurs after a minority of cycles but which may occur in over half of all patients.
Kaposi's sarcoma (KS) is the most common neoplasm complicating the acquired immunodeficiency syndrome (AIDS) with a prevalence ranging from 15% to 35% (Centers for Disease Control, 1986; Peters et al., 1991; Des Jarlais et al., 1987) .
Although the incidence of epidemic KS has declined, greater numbers of affected patients are developing more severe forms of the disease with gastrointestinal, respiratory or lymphatic involvement (Des Jarlais et al., 1987) . As a consequence, KS has become an increasingly important cause of morbidity and mortality among AIDS patients.
Cytotoxic chemotherapy, often involving doxorubicin, has been the mainstay of treatment for severe KS. Various multior single-agent regimens, however, have demonstrated either limited efficacy or significant toxicity (Laubenstein et al., 1984; Mintzer et al., 1985; Gelmann et al., 1987; Volberding et al., 1985; Gill et al., 1990a and b; Kaplan et al., 1986; Lassoued et al., 1990) . No regimen has been shown to increase patient survival (Volberding et al., 1989) and treatment is undertaken for purposes of palliation. Stealth liposomes are small (100 nm) unilamellar liposomes which bear molecules of polyethylene glycol (PEG) on their surface. The polymer groups provide a steric barrier that stabilises the liposomes in plasma, thereby reducing recognition and uptake by the reticuloendothelial system and prolonging circulation time relative to conventional liposomes (Papahadjopoulos et al., 1991) . They have also been shown to deliver significantly greater quantities of doxorubicin to highly vascular KS lesions than to normal skin (Northfelt et al., 1995) . This multicentre phase II study, the largest study to Exclusion criteria included the presence of active opportunistic infection or non-Hodgkin's lymphoma, the administration of systemic chemotherapy or radiotherapy within 3 weeks before entry into the trial (or within 8 weeks in the case of previous treatment with mitomycin, nitrosoureas or platinum compounds), allergy to anthracyclines, previous cumulative anthracycline dose> 200 mg m-2 and the presence at baseline of any one of the following: WBC<2000 mm-3; granulocyte count< 1000 mm-3; Hb <10 g dl-'; platelet count<75 000 mm-3; prothrombin time> twice the upper limit of normal; serum bilirubin>2.0 mg dl-'; serum transaminase or alkaline phosphatase levels > 2. Patients were evaluated weekly for toxicity; complete blood counts were performed within 48 h before dosing throughout the study. Biweekly efficacy evaluation included evaluation of tumour response (after at least two cycles of therapy), assessment of Karnofsky status and completion of the quality-of-life questionnaire. Patients were to be withdrawn from the study if KS did not respond or had progressed after four doses of SL-DOX. Patients were also to be withdrawn in the event of profound and persistent neutropenia, anaemia or thrombocytopenia, biochemical abnormalities, intercurrent illness interfering with participation, pregnancy, patient request, investigator discretion or evidence of cardiotoxity. Echocardiography was repeated after every four cycles when the cumulative dose of doxorubicin exceeded 400 mg m-2.
Quality of life was evaluated in 214 patients using a 37-item self-assessment questionnaire that included five domains: functional ability (ten items), pain (two items), KS-specific questions (four items), body image (three items) and physical condition (18 items). The first seven questions were yes/no questions relating to activities of daily living. The remaining 30 items had various anchored categorical responses and addressed general physical health as well as issues related specifically to Kaposi's sarcoma and body image. Patients began treatment at 10 mg m-2 or 20 mg m-2 depending on investigator discretion, and the dose was titrated upwards if KS lesions failed to respond. During the trial, dose could be titrated downward in the event of toxicity. As a result of disease progression, ten patients received doses of SL-DOX other than 10 mg m-2, 20 mg m-2 or 40 mg m-2 at the discretion of the investigators.
Prophylaxis against Pneumocystis carinii pneumonia (PCP) was encouraged and concomitant nucleoside therapy permitted. Growth factor support was also permitted to manage neutropenia.
Statistical methods
In the time-to-event analyses (cycle number at BR, time to BR, days to treatment failure, etc.) the mean, standard error, median and range are computed from Kaplan-Meier curves. In the analysis of the quality-of-life questionnaire, change within each patient from baseline to the time of the best KS response was analysed using a paired t-test.
Results Patients
A total of 247 patients were enrolled. Patient demographics are given in Table I , baseline presentation of KS in Table II and TIS staging of KS in Table III . The median baseline CD4 count for the 228 patients in whom it was measured was 30.5 mm-'. Of these patients, 199/228 (87.3%) had CD4 counts < 200 mm-3.
One hundred and sixty-two patients (65.8%) received prophylaxis against opportunistic infection during the course of the trial. Of these 162 patients, 97 received sulphamethox- Figure 1 . Treatment failure (defined as the development of progressive disease after the patient had achieved his best response) occurred in 73/238 patients or 30.7% (Table V) . Patients whose BR was progressive disease were omitted from the time-to-treatment-failure analysis.
There Liposomal doxorubicin has demonstrated efficacy against a variety of murine tumours including human xenografts (Vaage et al., 1992) . Phase I clinical trials in cancer patients showed that Stealth liposomal doxorubicin had a long plasma half-life and increased accumulation in malignant effusions relative to comparable doses of conventional doxorubicin (Rahman et al., 1990; Gabizon et al., 1994) . These findings suggested that Stealth liposomal doxorubicin could have significant advantages over the conventional formulation of doxorubicin in the treatment of KS patients.
In this study, over 80% of patients had a best response of either CR or PR when SL-DOX was administered biweekly. These results compare favourably with those obtained in a study involving 53 AIDS patients with KS given 15 mg m-2 conventional doxorubicin weekly (Fischl et al., 1993) .
Only two patients completed this study from which 47 of 53 evaluable patients were withdrawn after a median treatment duration of 2.7 months. Seventeen of these patients (32%) were withdrawn because of toxicity and 13 (24.5%) were withdrawn because of progressive KS. Among 50 patients evaluable for efficacy, none had a CR, five (10%) had a PR, 32 (64%) had a minor response, 12 (24%) no change and one (2%) progression as their best response.
In a second study involving 33 patients who were treated biweekly with a regimen incorporating conventional doxorubicin (10 mg m-2 or 20 mg m-2), bleomycin 10 mg m-2 and vincristine (1.4 mg m-2, 2 mg maximum) (Gill et al., 1990b) , 26/33 patients (79%) had either a partial (18 patients) or complete (eight patients) response. These responses were achieved after a median of six cycles. In terms of toxicity, 11 patients (33%) developed neutrophil counts <1000 mm-3, 19 (58%) experienced nausea and/or vomiting and 20 (61%) developed alopecia. Vincristine-related neuropathy occurred in 20 patients (61 %) and in two the severity of the neuropathy required discontinuation of vincristine after one or two cycles.
Other, non-anthracycline-containing chemotherapeutic regimens have employed etoposide, vincristine, vinblastine or bleomycin as single agents (Laubenstein et al., 1984; Mintzer et al., 1985; Volberding et al., 1985; Lassoued et al., 1990) , or two-drug combinations of vincristine and bleomycin (Gill et al., 1990a), or vincristine and vinblastine (Kaplan et al., 1986) . Alpha-interferon is also used as a single agent (Gelmann et al., 1987; Lane et al., 1988 The patient in whom fulminant hepatic necrosis was ascribed to SL-DOX has been described elsewhere (Hengge et al., 1993) . This patient, who entered the study with elevated levels of hepatic enzymes, suffered from chronic active hepatitis B infection and had been heavily treated with fluconazole for oesophageal candidiasis shortly before his death. It was postulated that the hepatic necrosis seen in this patient resulted from the combined effects of drug-and virusinduced hepatitis.
Palmar -plantar erythrodysaesthesia syndrome was described in four patients in this trial. This syndrome is typically manifest as a prodrome of dysaethesias involving the hands and feet in which an initial tingling progresses over 3 -4 days to discomfort and then to pain which is accompanied by symmetrical swelling and erythema of the palms, fingers and soles. If therapy is interrupted, resolution takes place over 5-14 days with desquamation of the affected skin. This syndrome has been reported to occur both with SL-DOX (Gordon et al., 1995) and with continuous infusion of doxorubicin (Lokich and Moore, 1984) . In one series of 36 patients who received long-term, low-dose continuous infusion of doxorubicin (Vogelzang and Ratain, 1985) , 15 of 32 patients treated for more than 30 days developed erythrodysaesthesia. This suggests a causal relationship between the persistence of doxorubicin in the blood and the occurrence of the syndrome. Such a relationship is consistent with the significantly prolonged tl/2 and AUC for doxorubicin that are achieved by incorporating this agent in Stealth liposomes (Northfelt et al., 1995) .
Since the mean cumulative anthracycline exposure in this trial was relatively low (144 mg m-2), significant cardiotoxicity would not have been expected. Moreover, the occurrence of HIV-associated cardiomyopathy (Grody et al., 1990) complicates interpretation of the adverse cardiac experiences observed here.
The 53.5% incidence of opportunistic infection on therapy in this trial compares favorably with rates in most trials of other chemotherapeutic regimens. In these trials, opportunistic infections occurred in 11-89% of patients (Laubenstein et al., 1984; Gill et al., 1990a,b; Fischl et al., 1993; Gill et al., 1991) . Moreover, given that 80.6% of all patients had CD4 counts on entry <200 mm-3 and that at least a third of all trial participants received no form of prophylaxis against Pneumocystis carinii pneumonia, the 24 cases of PCP reported here would not have been unanticipated (Masur et al., 1989; Fischl et al., 1988; Hirschel et al., 1991; Freedberg et al., 1991) . The same holds true for the 44 cases of cytomegalovirus-related disease given the relationship between the probability of developing such disease and CD4 counts< 100 mm-3 (Gallant et al., 1992) .
A trial comparing single-agent therapy with SL-DOX to combination therapy with doxorubicin, vincristine and bleomycin (ABV) is ongoing and will assess the relative safety and efficacy of these two regimens. Phase I trials of SL-DOX have indicated that SL-DOX has activity in breast, ovarian, head and neck, prostatic, renal cell and non-smallcell lung carcinomas (Uziely et al., 1995 
